Improvement in advanced Alzheimer’s disease following high-dose psilocybin

Study design, quality, and claims

• Thread emphasizes this is a single-patient case report, not a clinical trial.
• Multiple commenters highlight red flags: n=1, pay-to-publish journal, minimal diagnostic detail (“compatible with Alzheimer’s”), no clear pre-/post- standardized testing, uncontrolled street-sourced mushrooms.
• Some say clinicians and researchers routinely see such “miracle case reports” and treat them as anecdotes until replicated; they argue this paper adds little illumination to the field.
• Others counter that even weak case reports can spark new lines of inquiry in a field that has seen limited progress on Alzheimer’s.

Reported effects and mechanisms

• The described improvements (speech, continence, mobility, social engagement) lasting days to weeks are seen as striking, though explicitly “transient,” not disease reversal.
• Comments connect this to existing psychedelic findings: increased neural connectivity, default mode network modulation, neuroplasticity, and “reset” of brain networks, but note mechanisms remain unclear.
• Some speculate it may be analogous to “overclocking” residual function or to terminal lucidity, where late-stage patients briefly regain clarity near death.

Dose, safety, and subjective experience

• Strong debate around the 5 g mushroom dose, especially given it was a very potent strain.
• Many describe 5 g dry as a “heroic” or intense dose; a few argue it’s only a light/moderate dose based on commercial truffle products, with confusion over wet vs. dry weight.
• Personal anecdotes range from transformative experiences to hospitalization after very high doses.

Ethics and consent

• Major concern over giving such a high psychedelic dose to someone with advanced cognitive impairment.
• Critics question whether regaining lucidity only to lose it again constitutes avoidable suffering, especially with only short-lived benefit.
• Others stress the potential value of “one last real conversation” for families.
• Some note that doctors have broad latitude in individual treatment; consent from a legal guardian is standard when patients lack capacity, though this feels ethically uncomfortable to some commenters.

Hype, grift, and broader psychedelic context

• Several comments warn about hype cycles around psychedelics, low-quality mental health studies, and commercial actors promoting derivative compounds or delivery systems.
• There is discussion of regulatory barriers (Schedule I status) versus a recent political push to accelerate psychedelic approvals.
• Overall tone: cautious interest, with many urging rigorous controlled trials before drawing conclusions.